SCHEMBL1476922

SCHEMBL1476922

N#Cc1cncc(C=Cc2cccc(Br)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 2/20 0.61
MAOB P27338 3/20 0.46
MAOA P21397 2/20 0.46
P4HB P07237 2/20 0.44
HSD17B3 P37058 1/20 0.41
FBP1 P09467 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP1B1 Q16678 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ADORA2A P29274 1/20 0.37
AURKA O14965 1/20 0.36
KDR P35968 1/20 0.36
AKT1 P31749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476920 1.00 RAF1 (0.61) RAF1MAOBMAOAP4HBHSD17B3
SCHEMBL16635414 0.88 RAF1 (0.54) RAF1MAOBMAOAP4HBFBP1
SCHEMBL16635416 0.88 RAF1 (0.54) RAF1MAOBMAOAP4HBFBP1
SCHEMBL1477004 0.87 RAF1 (0.68) RAF1MAOBMAOAP4HBFBP1
SCHEMBL1477006 0.87 RAF1 (0.68) RAF1MAOBMAOAP4HBFBP1
SCHEMBL1476902 0.82 RAF1 (0.65) RAF1ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL1476900 0.82 RAF1 (0.65) RAF1ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL1477161 0.82 RAF1 (0.61) RAF1MAOBMAOAFBP1CYP1A1
SCHEMBL1477163 0.82 RAF1 (0.61) RAF1MAOBMAOAFBP1CYP1A1
SCHEMBL1477145 0.78 RAF1 (0.57) RAF1MAOBMAOAP4HBFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915424-B2 Analgesics; anxiolytic agents ELI LILLY AND COMPANY (US) 2011-03-29 US disclosed
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP disclosed
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists ELI LILLY AND COMPANY (US) 2008-08-14 US disclosed
EP-1729771-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2006-12-13 EP disclosed
WO-2005094822-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists HRH4, CNR2, CNR1 RAF1 4597/4885MAOB 1112/4885MAOA 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.